2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 252-254
Access, Representation, Population Health, Treatment Considerations, Biological Therapies, Transplantation, Women’s Health, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Bleeding and Clotting, Thrombotic Disorders, Immunology, Neutropenia, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pregnant, Young Adult
PAPER

724 Impact of Duffy status on relative dose intensity (RDI) and overall survival (OS) in KRAS wild type colorectal cancer (CRC): A post hoc analysis of cancer and leukemia group B (CALGB; Alliance)/SWOG 80405

Lauren E Merz, MD, MSc, Heather Gunn2, Shaylene McCue3, Fang-Shu Ou, PhD4, Jeffrey Meyerhardt5, Alan Venook6, Shaun Riska, MS7, Nicholas Larson8, Lucile Adams-Campbell9, Andrew Hantel, MD, MPH10
1 University of Michigan, Ann Arbor, Michigan, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 University of San Francisco, San Francisco, California, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Georgetown University, Washington, District of Columbia, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Introduction: Duffy null (DN) is a non-pathologic variant that results in lower absolute neutrophil counts (ANC) and is found in 66% of Black Americans and <1% of White Americans. Cytotoxic chemotherapy doses are often reduced for low ANC regardless of Duffy status, and reduced RDI is associated with inferior outcomes. Additionally, Black patients have inferior OS compared to White patients in CRC. Thus, we hypothesized that patients with the DN variant have a lower RDI, which may partially explain persistent racial disparities in cancer outcomes such as OS.

Methods: CALGB/SWOG 80405 was a phase III trial that randomized patients with advanced or metastatic KRAS wild type CRC receiving the cytotoxic chemotherapy backbones of mFOLFOX6 or FOLFIRI to cetuximab, bevacizumab, or the combination. The primary analysis found no significant differences in OS by treatment arm (Venook, JAMA 2017). In this post hoc analysis, Duffy status was determined by GWAS-derived rs2814778 alleles and categorized as DN or Duffy non-null (DNN). Self-defined races were categorized as Black or non-Black (all other races). The primary endpoint was RDI by Duffy status within each chemotherapy backbone. RDI was defined as the ratio of the delivered to the standard cytotoxic chemotherapy dose over the first two planned 8‑week treatment cycles. For patients who discontinued treatment because of disease progression, death, alternative therapy, or another complicating illness, the standard dose denominator was truncated at the time of discontinuation; otherwise, the full planned 16-week dose was used. Median and dichotomized RDI >/<90% were compared using Kruskal-Wallis and chi-square tests. The secondary endpoint was OS by Duffy and Duffy-Race status, estimated using the Kaplan–Meier method and compared between groups using the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression without other variables included as covariates.

Results: Of the 2134 patients eligible and randomized, 1305 (61.2%) had Duffy status available (87 DN and 1218 DNN); 94.3% DN patients were classified as Black and 60.7% of Black patients were DN. Median pre-treatment ANC for DN patients was 4.1 (Interquartile Range [IQR] 2.9, 5.4) versus 5.2 for DNN (IQR 4.0, 6.5; p<0.001). There were no significant differences for other demographic, clinical, or disease characteristics.

Among patients receiving mFOLFOX6, median RDI was similar among DN and DNN patients (83.7% vs 85.2%, p=0.33); 73.8% and 61.7% of DN and DNN patients were below the 90% RDI threshold (p=0.06). Among patients receiving FOLFIRI, median RDI was similar among DN and DNN patients (90.8% vs 85.0%, p=0.37); 48.0% and 58.9% of DN and DNN patients were below the 90% RDI threshold (p=0.29).

Median OS was lower for DN patients versus DNN patients (24.7 vs 28.8 months; HR=1.26, 95% CI 1.00-1.58; p=0.0499). This difference was maintained when restricted to Black individuals, with OS lower for Black DN versus DNN patients (23.9 vs 30.1 months; HR=1.46; 95% CI 1.00-2.11; p=0.047), while OS between Black DNN and non-Black DNN patients was similar (30.1 vs 28.6 months; HR=0.87, 95% CI 0.65-1.17; p=0.36). 

Conclusion: In this post hoc analysis of CALGB/SWOG 80405, DN status was associated with lower baseline ANC and inferior OS, but no differences in RDI. Survival was lower for DN versus DNN patients, and this difference was maintained among Black patients, suggesting that DN status rather than race may predict inferior outcomes. We did not see differences in RDI by DN status using an early treatment-period definition. RDI in metastatic cancer treatment is difficult to define when treatment duration is influenced by progression, toxicity, and discontinuation. Alternative RDI measures (e.g., no truncation, beyond early treatment) will be needed to determine if treatment dosing or other factors mediate the survival differences by Duffy status. These findings suggest that DN status identifies a subgroup with worse outcomes, but the mechanism remains unclear. Analyses of other oncology clinical trials are needed to determine whether DN status is a consistent predictor of inferior OS and the extent to which these associations are mediated by RDI.

Support: UG1CA189823, U10CA180821, U10CA180882;
https://acknowledgments.alliancefound.org

Lauren E Merz, MD, MSc: 23andMe - Consultancy (Includes expert testimony); Johnson&Johnson - Consultancy (Includes expert testimony)